- Bimekizumab - a new treatment option for axial spondyloarthritis2023 | First Faculty of Medicine
- Immunopathological inflammation in patients with psoriasis is effectively reduced by bimekizumab treatment targeting simultaneously IL-17A and IL-17F2023 | Faculty of Medicine in Hradec Králové
- Bimekizumab v léčbě psoriázy2022 | First Faculty of Medicine
- IL-17 inhibitors in psoriasis treatment2022 | Third Faculty of Medicine